ReviewThe Impact of COVID-19 On Comorbidities: A Review Of Recent Updates For Combating It
Under a Creative Commons license
open access
Graphical abstract
Keywords
Comorbidities
SARS-CoV-2
Complications
Variants
Mortality
Abbreviations
AD
Alzheimer’s Disease
ACE-2
Angiotensin-converting enzyme-2
AMI
Acute Myocardial Infarction
AIA
Avian Influenza A
HCQ
Hydroxychloroquine
ANE
Acute Necrotizing Encephalopathy
ARBs
Angiotensin receptors blockers
COPD
chronic obstructive pulmonary disease
CAP
Community-Acquired Pneumonia
CVS
Cardiovascular
CVDs
cardiovascular diseases
CDCP
Centres for Disease Control and Prevention
CF
Cardiac failure
CHD
Coronary heart disease
DM
Diabetes Mellitus
DIC
Disseminated intravascular coagulation
FLAIR
Fluid-Attenuated Inversion Recovery
GBS
Guillain-Barre Syndrome
G+C
Guanine + Cytosine
HLH
Hemophagocytic Lymphohistiocytosis
HT
Hypertension
ICUs
Intensive care units
IVIG
Intravenous immunoglobin, KIMII-Kawasaki-identical to multisystem inflammatory illness
KMS
Kasabach-Merritt Syndrome
MI
Myocardial infarction
NDs
Neurological disorders
NSTEMI
Non-ST-elevated myocardial infarction
PCI
Percutaneous Coronary Intervention
PPE
Personal protective equipment
pRb
Retinoblastoma protein
RNS
Reactive Nitrogen Species
BP
Blood pressure
ROS
Reactive oxygen species
SEM
Scanning electronic microscope
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
SIRS
Systemic inflammatory response syndrome
STEMI
ST-elevated myocardial infarction
PD
Parkinson’s Disease
Cited by (0)
Peer review under responsibility of King Saud University.
- 1
These authors contributed equally.
© 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.